Introduction
============

The incidence of esophageal cancer (EC) has been rapidly increasing in the United States.[@b1-cmar-10-3657] It was estimated that \>16,910 new EC patients would be diagnosed in 2016; however, the survival of EC patients is still poor and the 5-year overall survival was \<30%.[@b2-cmar-10-3657] Although most EC patients were diagnosed at an advanced stage, \>50% of patients had potential opportunity to receive R0 resection after preoperative treatment.[@b3-cmar-10-3657] Due to the higher therapeutic efficacy, preoperative radiotherapy (pRT) had been widely applied in non-metastatic esophageal cancer (nMEC) patients over the last decade.[@b4-cmar-10-3657],[@b5-cmar-10-3657] However, the model which can predict survival benefit from pRT followed by resection in nMEC remains unclear.

Currently, the American Joint Committee on Cancer (AJCC) staging system has been widely used in the survival prediction of nMEC patients.[@b6-cmar-10-3657] However, the prognosis value of this conventional prognosis model in the era of multimodal therapy for nMEC patients is unclear.[@b7-cmar-10-3657] Recently, response to therapy has been regarded as a stable survival predictor for EC patients. Based on the status of response to pRT, the patients can be divided into pathological complete response (pCR) group and non-pCR group. However, only 25% patients could achieve pCR, and \>75% of nMEC patients were pathologically confirmed with tumor residual after surgery.[@b8-cmar-10-3657],[@b9-cmar-10-3657] In addition, this classification oversimplifies the different prognostic categories for nMEC patients, and the variation of outcomes in intra-group patients cannot be accurately predicted by this prognostic model. In fact, this strategy solely depends on the final pathological stage for stratifying patients, but patients' other characteristics, such as age, location, sex, and grade, which can also affect survival were ignored. Thus, we hypothesize a prognostic model which can incorporate more risk factors and provide more accurate survival prediction.

As a simple predictive tool, nomogram has been established in several types of carcinoma and proved to predict survival accurately and effectively under clinical conditions.[@b10-cmar-10-3657]--[@b14-cmar-10-3657] However, the nomogram for nMEC patients after pRT has not been well established. In this study, based on multi-institution and multi-population data from Surveillance, Epidemiology, and End Results (SEER) database, we aimed to establish a nomogram to predict the survival of nMEC patients who underwent pRT followed by surgery.

Methods
=======

Patients
--------

The SEER program is one of the largest national collaboration programs by the National Cancer Institute. It collects and publisheŝ26% of American population's cancer incidence and survival information. In the current study, a retrospective review was performed between 1998 and 2013 of all nMEC patients who underwent pRT followed by surgery from SEER database. The study was limited to patients with non-distant organ metastasis disease. In order to evaluate the effect of lymph node status, patients with total examined lymph nodes (TLNs) \>0 were included in the current study. Finally, a total of 2,424 nMEC patients who met all the inclusion criteria were selected as primary cohort. Approximately, 80% (n=1,948) of patients from the primary cohort were randomly selected and designated as training data set, and the remaining (n=476) patients were defined as external validation set.

Ethical approval
----------------

SEER data are de-identified before release and do not contain any personally identifying information. As the data is publicly available, no ethical approval is required.

Data collection
---------------

To determine which factors were associated with the survival of nMEC patients who underwent pRT, the information regarding patients' clinicopathological characteristics, such as age at diagnosis, sex, race, treatment (surgery and radiotherapy), tumor location, histology, tumor size, grade, yp-T stage, the number of positive lymph nodes (PLNs), TLNs, and yp metastatic lymph node ratio (yp-mLNR), was collected. Yp-mLNR was defined as PLN divided by TLN. According to the seventh edition of AJCC staging system, the pathological tumor stage, yp-T stage, and yp-N stage were all restaged. The end point was disease-specific survival (DSS) rate, which was defined as the time form surgery to cancer-related death or the last follow-up. DSS estimation and survival curves were performed by Kaplan--Meier method and validated by the log-rank test.

Development of the prognostic nomogram
--------------------------------------

The nomogram was established as described previously in our study.[@b11-cmar-10-3657],[@b13-cmar-10-3657] Briefly, before the model was established, the linear relationships between continuous variables and the patients' survival were evaluated by restricted cubic spline analysis. Before modeling, the variables were translated into adequate forms to fit the linearity assumption. The best cutoff points for continuous variables were identified by X-tile software (<http://www.tissuearray.org/rimmlab/>). By the forward stepwise selection, the variables which were independently associated with DSS were identified by the Cox proportional hazards (PH) regression analysis. Based on the results of multivariable Cox PH regression, the nomogram that can provide 1-year, 3-year, and 5-year individualized DSS for nMEC patients was constructed.

Validation and visualization of the nomogram
--------------------------------------------

The nomogram was externally validated by the validation set. To test the prognostic accuracy, the nomogram validated both model discrimination and model calibration. First, the discrimination of nomogram was evaluated by Harrell's C-index, which can estimate the probability coherence between the predicted and observed outcomes. Discrimination between the established nomogram and the AJCC staging system was compared by R software. Next, calibration was carried out first by grouping all the patients in validation set, and then comparing the relationship between the predicted and the observed outcomes in all the groups.

Statistical analysis
--------------------

In the current study, *p*\<0.05 is considered as statistically significant. All the statistical analyses were performed by the R software version 3.1.3 (<http://www.r-project.org/>) and the software Statistical Package for Social Sciences version 19.0 (SPSS, Chicago, IL, USA).

Results
=======

Patients
--------

Between 1998 and 2013, a total of 2,424 nMEC patients who underwent pRT were identified from SEER database. Overall, the mean age at diagnosis was 60.7±9.5 years. There were 2,058 (84.9%) male patients and 366 (15.1%) female patients. The majority of patients were white (91.6%). Tumors in 2,031 (83.8%) patients were located in the lower third of esophagus, while 1,524 (62.9%) patients were diagnosed as lymph node-negative by pathological confirmation. The mean TLN was 13.3+9.7 (range: 1 to 83). The median follow-up time was 33.7 months. The 1-year, 3-year, and 5-year DSS rates were 80.4%, 49.8%, and 40.6%, respectively. Of those, 1,948 patients were randomly grouped into training set, and the remaining patients (n=476) were assigned to external validation set. The clinicopathological characteristics of the patients included in the training set and validation set are listed in [Table 1](#t1-cmar-10-3657){ref-type="table"}.

Factors
-------

According to the Harrell's theory, only those factors that fit into the PH and linearity assumptions can be included into the prognostic model. Thus, the continuous variables were transformed to adequate forms before modeling. The X-tile analysis showed that the best cutoff points of age at diagnosis were 54 and 72 years ([Figure S1](#SD1-cmar-10-3657){ref-type="supplementary-material"}). For clinical use, the best cutoff points were defined as 50 and 70 years for age at diagnosis. The age at diagnosis was translated into three parts (50≤, 51--69, and ≥70 years). The best cutoff point for TLN was identified as 8 ([Figure S2](#SD2-cmar-10-3657){ref-type="supplementary-material"}).

As shown in the [Figure 1A](#f1-cmar-10-3657){ref-type="fig"}, the nMEC patients with negative lymph node status had significantly better survival than those with positive lymph node status (*p*\<0.001). In addition, according to the TLN of patients, patients with negative lymph node metastasis were divided into two groups. A unique yp-mLNRS 0 category was defined as yp-mLNR=0 and TLN \>8, and yp-mLNRS 1 was defined as yp-mLNR=0 and TLN ≤8. By the X-tile analysis, the best cutoff point of yp-mLNR for lymph node-positive metastatic nMEC patients was 29% ([Figure S3](#SD3-cmar-10-3657){ref-type="supplementary-material"}). For clinical use, the best cutoff point for nMEC patients with lymph node metastasis was 30%. Thus, as to following intervals, the yp-mLNRS was classified into four groups: the yp-mLNRS 0 was defined as yp-mLNR=0% and TLN \>8; yp-mLNRS 1 as yp-mLNR=0% and TLN ≤8; yp-mLNRS 2 as 0% \< yp-mLNR ≤30.0%; and yp-mLNRS 3 as 30.0% \< yp-mLNR \< 100% ([Figure 1B](#f1-cmar-10-3657){ref-type="fig"}). The 5-year DSS rates for the four-level yp-mLNRS categories were 57.5%, 45.0%, 26.9%, and 11.3%, respectively.

Development of nomogram for esophageal cancer patients
------------------------------------------------------

In the multivariable Cox analysis, the patients' age at diagnosis, sex, tumor location, tumor grade, yp-T stage, and yp- mLNRS can independently predict patients' DSS ([Table 2](#t2-cmar-10-3657){ref-type="table"}). Therefore, all the independent risk factors which were statistically associated with DSS were incorporated into the prognostic nomogram ([Figure 2](#f2-cmar-10-3657){ref-type="fig"}), and the C-index value was 0.67 by bootstrap validation.

Validation of the proposed nomogram
-----------------------------------

The external validation of the proposed nomogram was performed in validation set. The predictive ability of the proposed nomogram was compared with the seventh edition of AJCC staging system for EC. The validation of the proposed nomogram was performed in two directions. First, the C-index of the proposed nomogram was 0.62 (95% CI, 0.58 to 0.66), which was obviously better than that of the seventh AJCC staging system (0.55, 95% CI, 0.51 to 0.60; *p*\<0.001). Second, as shown in [Figure 3](#f3-cmar-10-3657){ref-type="fig"}, the probabilities of 1-year, 3-year, and 5-year DSS rates in the proposed nomogram were optimally close between the survival predictions and observations.

Subset analysis
---------------

Given the fact that esophageal adenocarcinoma patients and esophageal squamous cell carcinoma patients respond differently to the pRT, we made a subset analysis by the histological type. Based on the histological type of patients, the primary cohort was divided into two validation cohorts. Patients with adenocarcinoma type were designed as adenocarcinoma validation set, and the patients with squamous cell carcinoma were defined as squamous cell carcinoma validation set. In adenocarcinoma validation set, the C-index of proposed nomogram was 0.65 (95% CI, 0.62 to 0.67), which was significantly higher than that proposed by the AJCC staging system (0.61, 95% CI, 0.60 to 0.63; *p*\<0.001). Additionally, the results were similar in the squamous cell carcinoma validation set. Compared with the AJCC staging system, the proposed nomogram exhibited a more accurate survival prediction in the squamous cell carcinoma validation set (0.63 vs 0.52, *p*\<0.001). As shown in [Figure 4](#f4-cmar-10-3657){ref-type="fig"}, the predicted DSS rate was within a 10% margin of actual outcomes in adenocarcinoma validation set and squamous cell carcinoma validation set.

Discussion
==========

In the current study, we first established and validated a prognostic nomogram to predict DSS for nMEC patients who underwent pRT. On comparison with the seventh edition of AJCC staging system, we found the proposed nomogram exhibited more accuracy in DSS prediction of nMEC patients who underwent pRT (C-index: 0.62 vs 0.55, *p*\<0.001), regardless of the patient's histological type.

The use of prognostic model for predicting the survival of nMEC patients who underwent preoperative treatment is still controversial. In 2014, based on the SEER-Medical database, Eil et al established a nomogram for nMEC patients who received neoadjuvant chemoradiotherapy followed by surgery or surgery only.[@b15-cmar-10-3657] The prognostic model included patients' age at diagnosis, sex, histology, yp-T stage, yp-N stage, TLN, and treatment. It exhibited a wonderful survival prediction for those patients (C-index: 0.72). However, the primary cohort of this nomogram included 562 (68%) patients who received esophagectomy only (the remaining patients underwent neoadjuvant chemoradiotherapy). Given the tumor downstaging of neoadjuvant chemoradiotherapy, the survival of patients undergoing esophagectomy may differ from the patients with neoadjuvant therapy even if they had the same pathological stage. It may underestimate the survival benefit for the patients without neoadjuvant chemoradiotherapy. A nomogram only for the patients receiving neoadjuvant therapy may provide more accuracy in survival prediction. In 2016, based on the 626 patients who had received neoadjuvant chemoradiotherapy from CROSS-I and CROSS-II trails, Shapiro et al established a nomogram to predict survival for the nMEC patients who underwent neoadjuvant chemoradiotherapy.[@b16-cmar-10-3657] This nomogram included clinical lymph node stage, yp-T stage, and yp-N stage and exhibited a more accurate survival prediction (C-index: 0.63). This study provided a novel model that can estimate individual survival for nMEC patients after preoperative chemoradiotherapy. However, both the training set and validation set were from tertiary care institutions that gave special treatments in nMECs, so selection bias cannot be ignored. In fact, the performance of this nomogram in predicting survival of nMEC patients in a general population was unclear. Moreover, several other important factors, such as mLNR, had not been analyzed.

mLNR, as a prognostic factor, has been analyzed and demonstrated as an independent survival predictor for EC patients in several studies. Those studies have found that mLNR may better stratify nMEC patients' survival than AJCC N staging system.[@b17-cmar-10-3657],[@b18-cmar-10-3657] However, the prognostic role of mLNR in nMEC patients after pRT has not been carefully evaluated. In the current study, based on a multi-institution and multi-population database, we first demonstrated that mLNR is associated with the survival of nMEC patients who underwent pRT followed by surgery. Furthermore, compared with lymph node stage, the mLNR stage can dramatically reduce the stage migration than the yp-N stage, regardless of the TLN. Interestingly, the proposed nomogram incorporating mLNR exhibited a more accurate survival prediction than the nomogram incooperating the number of metastatic lymph nodes (data not shown).

Although adenocarcinoma and squamous cell carcinoma respond differently to pRT,[@b19-cmar-10-3657],[@b20-cmar-10-3657] our study found that the pathological type was not associated with survival in nMEC patients treated with pRT followed by surgery. Thus, the proposed nomogram was derived from a cohort which included both adenocarcinoma and squamous cell carcinoma. Indeed, in the subset analysis, the proposed nomogram was found more accurate than AJCC staging system both in adenocarcinoma validation set and squamous cell validation set. Therefore, the proposed nomogram had a wider application for histological differences observed in nMEC patients.

Limitations
===========

There are some limitations that should be acknowledged. First, since only those patients who had complete information were included in the current study, selection bias may exist. Second, as this nomogram was based on SEER database, analysis was intrinsically limited by the SEER database, which included the lack of information regarding other important survival predictors. Several predictors such as surgical margins, genetic differences, protein expression differences, and postoperative treatments had not been analyzed in the current study.

Conclusion
==========

We first developed and validated a prognostic nomogram to provide an individual survival prediction for EC patients who underwent pRT. Compared with the seventh edition of AJCC staging system, the proposed nomogram exhibits a better prognostic discrimination and survival prediction. It can be used to calculate individualized survival prediction and provide better treatment allocation for EC patients.

Supplementary materials
=======================

###### 

X-tile analysis identified the best cutoff points for age at diagnosis.

**Notes:** The X-tile program divided the data of age at diagnosis into three groups. Statistical significance is assessed by using the cutoff point derived from a training set to parse a separate validation set. *p*-values were obtained from a standard log-rank test and plotted at the lookup table.

**Abbreviations:** Chi-Sq, chi square; Hi, high; Lo, low, Mid, median; Max, maximum; Pt No, patient number.

###### 

X-tile analysis identified the best cutoff points for total number of examined lymph nodes.

**Notes:** The X-tile program divided the data of total number of examined lymph nodes into two groups. Statistical significance was assessed by using the cutoff point derived from a training set to parse a separate validation set. *p*-values were obtained from a standard log-rank test and plotted at the lookup table.

**Abbreviations:** TLN, total examined lymph node; Chi-Sq, chi square; Hi, high; Lo, low; Max, maximum; Pt No, patient number.

###### 

X-tile analysis identified the best cutoff points for the yp-mLNR in the patients with lymph node metastasis.

**Notes:** The X-tile program divided the data of yp-mLNR into two groups. Statistical significance was assessed by using the cutoff point derived from a training set to parse a separate validation set. *p*-values were obtained from a standard log-rank test and plotted at the lookup table.

**Abbreviations:** mLNR, metastatic lymph node ratio; Chi-Sq, chi square; Hi, high; Lo, low, Mid, median; Max, maximum; Pt No, patient number.
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![**(A)** Disease-specific survival stratified by the lymph node status. (**B**) Disease-specific survival according to mLNR, stratified into four groups and validated by Kaplan--Meier curve.\
**Abbreviation:** mLNR, metastatic lymph node ratio.](cmar-10-3657Fig1){#f1-cmar-10-3657}

![Nomogram predicting 1-year, 3-year, and 5-year disease-specific survival for nMEC patients after pRT following surgery.\
**Abbreviations:** nMEC, non-metastatic esophageal cancer; pRT, preoperative radiotherapy; mLNR, metastatic lymph node ratio; mLNRS, metastatic lymph node ratio stage; DSS, disease-specific survival.](cmar-10-3657Fig2){#f2-cmar-10-3657}

![Calibration plot for predicting patients' DSS at 1 year (**A**), 3 years (**B**), and 5 years (**C**) in the validation set.\
**Notes:** The X-axis represents the predicted survival of nomogram, and on the Y-axis is plotted actual survival. The dotted line represents the ideal correlationship between predicted and actual survival.\
**Abbreviations:** DSS, disease-specific survival; SEER, Surveillance, Epidemiology, and End Results.](cmar-10-3657Fig3){#f3-cmar-10-3657}

![Calibration plots for predicting patients' DSS at 1 year (**A**), 3 years (**B**), and 5 years (**C**) in the adenocarcinoma validation set. Calibration plots for and predicting DSS at 1 year (**D**), 3 years (**E**), and 5 years (**F**) in the squamous cell carcinoma validation set.\
**Notes:** The X-axis represents the predicted survival of nomogram, and on Y-axis is plotted actual survival. The dotted line represents the ideal correlationship between predicted and actual survival.\
**Abbreviation:** DSS, disease-specific survival.](cmar-10-3657Fig4){#f4-cmar-10-3657}

###### 

Characteristics of training set and validation set

  Characteristics             Training set (n=1,948)   Validation set (n=476)              
  --------------------------- ------------------------ ------------------------ ---------- ------
  Age (years)                                                                              
   Mean                       60.7±9.5                                          60.5±9.3   
   Range                      23--87                                            23--82     
  Sex                                                                                      
   Male                       1,648                    84.6                     410        86.1
   Female                     300                      15.4                     66         13.9
  Race                                                                                     
   White                      1,798                    92.3                     423        88.9
   Black                      81                       4.2                      30         6.3
   API                        56                       2.9                      21         4.4
   AI                         10                       0.5                      2          0.4
   Unknown                    3                        0.2                      0          0
  Tumor location                                                                           
   Lower third of esophagus   1,636                    84.0                     395        83.0
   Others                     312                      16.0                     81         17.0
  Grade                                                                                    
   Well                       89                       4.6                      22         4.6
   Moderately                 802                      41.2                     197        41.4
   Poorly                     1,022                    52.5                     246        51.7
   Undifferentiated           35                       1.8                      11         2.3
  Pathological type                                                                        
   Adenocarcinoma             1,504                    77.2                     356        74.8
   Squamous carcinoma         401                      20.6                     110        23.1
   Adenosquamous carcinoma    43                       2.2                      10         2.1
  Yp-T stage                                                                               
   1                          246                      12.6                     68         14.3
   2                          373                      19.1                     89         18.7
   3                          1,217                    62.5                     290        60.9
   4                          112                      5.7                      29         6.1
  Yp-N stage                                                                               
   0                          1,205                    61.9                     319        67.0
   1                          468                      24.0                     104        21.8
   2                          206                      10.6                     39         8.2
   3                          69                       3.5                      14         2.9
  Yp-AJCC stage                                                                            
   IA                         78                       4.0                      28         5.9
   IB                         212                      10.9                     51         10.7
   IIA                        176                      9.0                      45         9.5
   IIB                        743                      38.1                     193        40.5
   IIIA                       515                      26.4                     110        23.1
   IIIB                       135                      6.9                      26         5.5
   IIIC                       89                       4.6                      23         4.8

**Abbreviations:** API, Asian or Pacific Islander; AI, American Indian or Alaska Native; AJCC, American Joint Committee on Cancer.

###### 

Selected results of multivariate analysis in the training set

  Characteristics             HR     95% CI         *p*-value
  --------------------------- ------ -------------- -----------
  Age (years)                                       0.039
   ≤50                        Ref                   
   51--69                     1.14   0.95 to 1.37   
   ≥70                        1.35   1.07 to 1.70   
  Sex (female vs male)        1.38   1.14 to 1.68   0.001
  Location                                          \<0.001
   Others                     Ref                   
   Lower third of esophagus   0.75   0.63 to 0.90   
  Grade                                             \<0.001
   Well                       Ref                   
   Moderately                 1.10   0.62 to 1.93   
   Poorly                     1.23   0.85 to 1.77   
   Undifferentiated           1.67   1.16 to 2.40   
  Yp-T stage                                        \<0.001
   1                          Ref                   
   2                          1.27   0.99 to 1.63   
   3 or 4                     1.51   1.21 to 1.87   
  Yp-mLNRS                                          \<0.001
   0                          Ref                   
   1                          1.57   1.30 to 1.88   
   2                          2.33   1.96 to 2.77   
   3                          3.66   3.02 to 4.45   

**Abbreviations:** HR, hazard ratio; Ref, reference; mLNRS, metastatic lymph node ratio stage.
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